Cumulase™ - Recombinant Hyaluronidase

Introducing rHuPH20 - The Only Recombinant Human Hyaluronidase

Cumulase™ is an ex vivo (used outside of the body) formulation of rHuPH20 to replace the bovine enzyme currently used for the preparation of oocytes (eggs) prior to in vitro fertilization (IVF) during the process of intracytoplasmic sperm injection (ICSI), in which the enzyme is an essential component. The enzyme strips away the hyaluronic acid that surrounds the oocyte. This allows the clinician to then perform the ICSI procedure, injecting the sperm into the oocyte.

The purity of Cumulase™ is more than 100-fold higher than the currently used animal preparations. It may reduce, if not eliminate, the risk of damage or trauma to the oocytes, and eliminates the risk of animal pathogen contamination, thereby providing a safer, purer, and more reliable alternative to bovine and ovine slaughterhouse-derived enzymes.

Cumulase™ Receives CE Mark

SAN DIEGO, Dec. 28 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Amex: HTI - News), a development stage biopharmaceutical company developing and commercializing recombinant human enzymes, today announced it has received CE (European Conformity) Mark approval for Cumulase(TM) for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The CE Mark demonstrates that the company is in compliance with the applicable European Union (EU) directives and allows the company to market Cumulase throughout the EU. The Company anticipates launching Cumulase early in the first quarter of 2005.

Ordering Informatin

#HAL-CUM-10X: 5 vials, 100 µl conc/vial, reconstituted to 1 ml

Download PDF Info Sheet
Visit the Hyalozyme Web Site

FDA released April 2005

Return to Top